{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:53:16Z","timestamp":1781895196433,"version":"3.54.5"},"reference-count":139,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years towards combination therapy, enhancing survival outcomes when compared with androgen deprivation therapy (ADT) alone. However, many patients who are eligible for combination therapy are still receiving ADT monotherapy, and a significant proportion of those treated with doublet combinations still experience suboptimal outcomes. Furthermore, the value of adding docetaxel to an androgen receptor pathway inhibitor (ARPI)\/ADT doublet in mHSPC has not been delineated, particularly in patients with low-volume disease, and chemotherapy toxicity and tolerability remain a major concern for patients. This review addresses the significant unmet need for additional or novel treatment strategies for mHSPC, utilizing prostate-specific membrane antigen (PSMA)\u2013targeted radioligand therapy (RLT) in a combination regimen that uses a non-chemotherapeutic approach for the treatment of mHSPC. PSMA-targeted RLT has been shown to improve survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with ARPIs +\/\u2212 taxanes and is now under evaluation for the treatment of mHSPC, given its demonstrated success in the mCRPC space. Thus, continued education on RLT and its use for patients with mHSPC is important to optimize patient care. This review provides a brief outline of the mHSPC treatment landscape, focusing on the challenges and unique considerations faced by healthcare professionals when treating these patients. We also evaluate the potential role of RLT in surmounting these challenges, discussing potential barriers and solutions to its integration as a treatment for mHSPC.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag173","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:49:29Z","timestamp":1778240969000},"source":"Crossref","is-referenced-by-count":0,"title":["The emerging role of prostate-specific membrane antigen\u2013targeted radioligand therapy in metastatic hormone-sensitive prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-1140","authenticated-orcid":false,"given":"Philipose","family":"Mulugeta","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia, PA 19104,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5990-298X","authenticated-orcid":false,"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hafron","sequence":"additional","affiliation":[{"name":"Michigan Institute of Urology , Troy, MI 48084,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Anh","family":"Huynh","sequence":"additional","affiliation":[{"name":"Massachusetts General Brigham Cancer Institute , Boston, MA 02115,","place":["United States"]},{"name":"Dana-Farber Cancer Institute , Boston, MA 02215,","place":["United States"]},{"name":"Department of Radiation Oncology, Harvard Medical School , Boston, MA 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K","family":"Morgans","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E","family":"Ross","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine , Chicago, IL 60611,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R","family":"McKay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Urology, and Radiation Medicine and Applied Sciences, University of California San Diego , La Jolla, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026061914100547200_oyag173-B1","year":"2025"},{"key":"2026061914100547200_oyag173-B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026061914100547200_oyag173-B3","author":"World Health Organization: International Agency for Research on Cancer","year":"2025"},{"key":"2026061914100547200_oyag173-B4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026061914100547200_oyag173-B5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026061914100547200_oyag173-B6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting","volume":"8","author":"Ng","year":"2020","journal-title":"Oncol Ther"},{"key":"2026061914100547200_oyag173-B7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MOU.0000000000001124","article-title":"Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions","volume":"33","author":"Zattoni","year":"2023","journal-title":"Curr Opin Urol"},{"key":"2026061914100547200_oyag173-B8","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2021.39.15_suppl.5074","article-title":"Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings","volume":"39","author":"George","year":"2021","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","article-title":"Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026061914100547200_oyag173-B11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026061914100547200_oyag173-B12","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (stampede): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"2026061914100547200_oyag173-B13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the extend phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026061914100547200_oyag173-B14","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (sabr-comet): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"2026061914100547200_oyag173-B15","doi-asserted-by":"publisher","first-page":"e390166","DOI":"10.1200\/EDBK_390166","article-title":"Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment","volume":"43","author":"Hamid","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2026061914100547200_oyag173-B16","doi-asserted-by":"publisher","first-page":"17588359221086827","DOI":"10.1177\/17588359221086827","article-title":"Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?","volume":"14","author":"Davis","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026061914100547200_oyag173-B17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.2147\/RRU.S360444","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: Patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol"},{"key":"2026061914100547200_oyag173-B18","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3390\/molecules27103062","article-title":"The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker","volume":"27","author":"Holik","year":"2022","journal-title":"Molecules"},{"key":"2026061914100547200_oyag173-B19","first-page":"S13","article-title":"Overview of prostate-specific membrane antigen","volume":"6 Suppl 10","author":"Chang","year":"2004","journal-title":"Rev Urol"},{"key":"2026061914100547200_oyag173-B20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"2026061914100547200_oyag173-B21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-0045(20000501)43:2<150::AID-PROS10>3.0.CO;2-B","article-title":"A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine","volume":"43","author":"Sokoloff","year":"2000","journal-title":"Prostate"},{"key":"2026061914100547200_oyag173-B22","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2026061914100547200_oyag173-B23","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res"},{"key":"2026061914100547200_oyag173-B24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"2026061914100547200_oyag173-B25","author":"Novartis","year":"2025"},{"key":"2026061914100547200_oyag173-B26","author":"Novartis Pharmaceuticals Corporation","year":"2025"},{"key":"2026061914100547200_oyag173-B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"Phase III trial of [177Lu]lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061914100547200_oyag173-B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/RLU.0000000000004919","article-title":"PSMA radioligand therapy in prostate cancer: Where are we and where are we heading?","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin Nucl Med"},{"key":"2026061914100547200_oyag173-B29","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"2026061914100547200_oyag173-B30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026061914100547200_oyag173-B31","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00345-022-04135-8","article-title":"Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer","volume":"41","author":"Chen","year":"2023","journal-title":"World J Urol"},{"key":"2026061914100547200_oyag173-B32","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061914100547200_oyag173-B33","author":"FDA Press Release","year":"2025"},{"key":"2026061914100547200_oyag173-B34","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.annonc.2025.07.003","article-title":"Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061914100547200_oyag173-B35","author":"Bayer","year":"2025"},{"key":"2026061914100547200_oyag173-B36","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"Arches: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026061914100547200_oyag173-B37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061914100547200_oyag173-B38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026061914100547200_oyag173-B39","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (latitude): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026061914100547200_oyag173-B40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"2026061914100547200_oyag173-B41","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (peace-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2026061914100547200_oyag173-B42","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2217\/fon-2022-0433","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial","volume":"18","author":"Smith","year":"2022","journal-title":"Future Oncol"},{"key":"2026061914100547200_oyag173-B43","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1200\/JCO.2022.40.16_suppl.5065","article-title":"Reasons for oncologist and urologist treatment choice in metastatic castration-sensitive prostate cancer (mCSPC): a physician survey linked to patient chart reviews in the United States","volume":"40","author":"Freedland","year":"2022","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","article-title":"Addition of docetaxel to androgen receptor axis\u2013targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"5","author":"Roy","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026061914100547200_oyag173-B45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41391-023-00696-w","article-title":"Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors","volume":"27","author":"Gebrael","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026061914100547200_oyag173-B46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.2024.42.4_suppl.126","article-title":"Differential treatment effect on overall survival (OS) based on early prostate-specific antigen (PSA) response in metastatic hormone-sensitive prostate cancer (mHSPC): a secondary analysis of titan trial","volume":"42","author":"Roy","year":"2024","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: Analyses of the randomized phase 3 ARASENS study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B48","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.3390\/curroncol30040332","article-title":"Triplet therapy in metastatic castrate sensitive prostate cancer (mCSPC)\u2014a potential new standard of care","volume":"30","author":"Mittal","year":"2023","journal-title":"Curr Oncol"},{"key":"2026061914100547200_oyag173-B49"},{"key":"2026061914100547200_oyag173-B50","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B51","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/1097-0142(20000615)88:12+<2989::AID-CNCR14>3.0.CO;2-Q","article-title":"The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma","volume":"88","author":"Carlin","year":"2000","journal-title":"Cancer"},{"key":"2026061914100547200_oyag173-B52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14737140.2023.2208352","article-title":"Emerging treatment options for prostate cancer","volume":"23","author":"Atiq","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026061914100547200_oyag173-B53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/curroncol32080437","article-title":"Evolving treatment paradigms in metastatic hormone-sensitive prostate cancer: Expert narrative review","volume":"32","author":"Talwar","year":"2025","journal-title":"Curr Oncol"},{"key":"2026061914100547200_oyag173-B54","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"2026061914100547200_oyag173-B55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in pten-deficient metastatic hormone-sensitive prostate cancer: Capitello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"2026061914100547200_oyag173-B56"},{"key":"2026061914100547200_oyag173-B57","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(25)00762-4","article-title":"(177)lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study","volume":"27","author":"Priv\u00e9","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026061914100547200_oyag173-B58","year":"2024"},{"key":"2026061914100547200_oyag173-B59","year":"2024"},{"key":"2026061914100547200_oyag173-B60","year":"2023"},{"key":"2026061914100547200_oyag173-B61","doi-asserted-by":"publisher","first-page":"E546","DOI":"10.1016\/j.ijrobp.2024.07.1209","article-title":"PSMAddition: Phase 3 trial of [177Lu]lu-PSMA-617 plus standard of care (soc) vs soc alone in patients with metastatic hormone-sensitive prostate cancer","volume":"120","author":"Kim","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026061914100547200_oyag173-B62","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (soc) and soc alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential (177) lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int"},{"key":"2026061914100547200_oyag173-B64"},{"key":"2026061914100547200_oyag173-B65","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [(177)lu]lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026061914100547200_oyag173-B66"},{"key":"2026061914100547200_oyag173-B67","year":"2024"},{"key":"2026061914100547200_oyag173-B68","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.7150\/thno.92612","article-title":"PSMA-targeted radiotheranostics in modern nuclear medicine: Then, now, and what of the future?","volume":"14","author":"Sallam","year":"2024","journal-title":"Theranostics"},{"key":"2026061914100547200_oyag173-B69","year":"2024"},{"key":"2026061914100547200_oyag173-B70","year":"2024"},{"key":"2026061914100547200_oyag173-B71","year":"2024"},{"key":"2026061914100547200_oyag173-B72","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061914100547200_oyag173-B73","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"2026061914100547200_oyag173-B74","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/JCO.2021.39.6_suppl.6","article-title":"177Lu-PSMA-617 (lupsma) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603)","volume":"39","author":"Hofman","year":"2021","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B75","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026061914100547200_oyag173-B76","author":"Tagawa","year":"2025"},{"key":"2026061914100547200_oyag173-B77","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1016\/j.ijrobp.2023.06.891","article-title":"A pilot study of stereotactic body radiotherapy and 177Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer","volume":"117","author":"Imber","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026061914100547200_oyag173-B78","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1158\/1078-0432.CCR-19-0006","article-title":"Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy","volume":"25","author":"West","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026061914100547200_oyag173-B79","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"2026061914100547200_oyag173-B80","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/15384047.2018.1423926","article-title":"Androgen receptor-independent prostate cancer: an emerging clinical entity","volume":"19","author":"Sahin","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"2026061914100547200_oyag173-B81","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1200\/JCO.2023.41.16_suppl.5033","article-title":"Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: the 3tmpo study","volume":"41","author":"Pouliot","year":"2023","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B82","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fonc.2015.00090","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure","volume":"5","author":"Hu","year":"2015","journal-title":"Front Oncol"},{"key":"2026061914100547200_oyag173-B83","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","article-title":"Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: Emerging opportunities and challenges","volume":"51","author":"Bakht","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B84","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00259-019-04635-7","article-title":"Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET\/MRI in men with treatment-na\u00efve prostate cancer","volume":"47","author":"Ettala","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B85","first-page":"654","article-title":"The effect of androgen deprivation therapy on PSMA expression evaluated with Ga-PSMA-11 PET\/MRI- a prospective, registered clinical trial","volume":"60","author":"Kemppainen","year":"2019","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B86","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","article-title":"Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 pet in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B87","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00259-018-4079-z","article-title":"Impact of long-term androgen deprivation therapy on PSMA ligand PET\/CT in patients with castration-sensitive prostate cancer","volume":"45","author":"Afshar-Oromieh","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B88","doi-asserted-by":"publisher","first-page":"S1255","DOI":"10.1016\/j.annonc.2024.08.2309","article-title":"Lba66 UpFrontPSMA: a randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (d) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"35","author":"Azad","year":"2024","journal-title":"Ann Oncol"},{"key":"2026061914100547200_oyag173-B89","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euo.2023.05.002","article-title":"Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201creal world\u201d? a systematic review","volume":"7","author":"Dodkins","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026061914100547200_oyag173-B90","year":"2025"},{"key":"2026061914100547200_oyag173-B91","author":"Novartis","year":"2025"},{"key":"2026061914100547200_oyag173-B92","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1097\/01.JU.0001015816.87470.c9.04","article-title":"Efficacy of [177Lu]lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)","volume":"211","author":"Shore","year":"2024","journal-title":"J Urol"},{"key":"2026061914100547200_oyag173-B93","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.7150\/thno.15311","article-title":"Potentiation of peptide receptor radionuclide therapy by the parp inhibitor olaparib","volume":"6","author":"Nonnekens","year":"2016","journal-title":"Theranostics"},{"key":"2026061914100547200_oyag173-B94","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"177)lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study","volume":"43","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914100547200_oyag173-B95","doi-asserted-by":"publisher","first-page":"17588359231157632","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: Current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026061914100547200_oyag173-B96","doi-asserted-by":"publisher","first-page":"S1630","DOI":"10.1016\/j.annonc.2025.09.105","article-title":"LBA89 a randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study pr.21","volume":"36","author":"Chi","year":"2025","journal-title":"Ann Oncol"},{"key":"2026061914100547200_oyag173-B97","doi-asserted-by":"publisher","first-page":"102524","DOI":"10.1016\/j.ctrv.2023.102524","article-title":"Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer","volume":"115","author":"Calais","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2026061914100547200_oyag173-B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21681805.2020.1851762","article-title":"Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: Registry-based study in Sweden","volume":"55","author":"Svensson","year":"2021","journal-title":"Scand J Urol"},{"key":"2026061914100547200_oyag173-B99","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of (177)lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B100","doi-asserted-by":"crossref","first-page":"TPS294","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS294","article-title":"Long-term safety outcomes of 177Lu-PSMA-617 in patients with prostate cancer","volume":"43","author":"Sartor","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026061914100547200_oyag173-B101","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with (177)lu-labelled PSMA-ligands ((177)lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B102","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B103","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-022-00891-1","article-title":"Bone marrow impairment during early [(177)lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression?","volume":"12","author":"Kind","year":"2022","journal-title":"EJNMMI Res"},{"key":"2026061914100547200_oyag173-B104","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION trial of [177Lu]lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B105","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2025.43.5_suppl.61","article-title":"Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617: a real-world prostate cancer disease observation (PRECISION) data platform analysis","volume":"43","author":"Wei","year":"2025","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B106","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","article-title":"Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients","volume":"66","author":"Wenzel","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"2026061914100547200_oyag173-B107","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"2026061914100547200_oyag173-B108","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12894-022-00979-9","article-title":"Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan","volume":"22","author":"Leith","year":"2022","journal-title":"BMC Urol"},{"key":"2026061914100547200_oyag173-B109","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2967\/jnumed.122.264144","article-title":"How many theranostics centers will we need in the United States?","volume":"63","author":"Czernin","year":"2022","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B110","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE v2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B111","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2967\/jnumed.121.263638","article-title":"Why we did what we did: PSMA PET\/CT selection criteria for the vision trial","volume":"63","author":"Kuo","year":"2022","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B112","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00330-023-10083-7","article-title":"Reliability and practicability of PSMA-rads 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients","volume":"34","author":"Grawe","year":"2024","journal-title":"Eur Radiol"},{"key":"2026061914100547200_oyag173-B113","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","article-title":"The primary score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B114","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B115","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/HP.0000000000001644","article-title":"Clinical best practices for radiation safety during lutetium-177 therapy","volume":"124","author":"Cappon","year":"2023","journal-title":"Health Phys"},{"key":"2026061914100547200_oyag173-B116","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00259-020-04745-7","article-title":"Realising the potential of radioligand therapy: Policy solutions for the barriers to implementation across Europe","volume":"47","author":"Merkel","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B117","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B118","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","article-title":"177)LU-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing (177)Lu-PSMA-I&T therapy","volume":"64","author":"John","year":"2023","journal-title":"J Nucl Med"},{"key":"2026061914100547200_oyag173-B119","doi-asserted-by":"publisher","first-page":"TPS5110","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5110","article-title":"A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT)","volume":"42","author":"Holzgreve","year":"2024","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B120","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/j.ijrobp.2024.07.1254","article-title":"Phase 2 prospective trial of re-treatment with 177lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA): study protocol","volume":"120","author":"Nikitas","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026061914100547200_oyag173-B121","year":"2024"},{"key":"2026061914100547200_oyag173-B122","year":"2024"},{"key":"2026061914100547200_oyag173-B123","doi-asserted-by":"publisher","first-page":"e6780","DOI":"10.1002\/cam4.6780","article-title":"Establishing a robust radioligand therapy program: a practical approach for North American centers","volume":"13","author":"Mittra","year":"2024","journal-title":"Cancer Med"},{"key":"2026061914100547200_oyag173-B124","doi-asserted-by":"publisher","first-page":"e13899","DOI":"10.1002\/acm2.13899","article-title":"Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: a case in lutetium-177 prostate-specific membrane antigen (PSMA) therapy","volume":"24","author":"Zoberi","year":"2023","journal-title":"J Appl Clin Med Phys"},{"key":"2026061914100547200_oyag173-B125","year":"2025"},{"key":"2026061914100547200_oyag173-B126","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s00259-023-06163-x","article-title":"Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 pet molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]lu-PSMA-617 radioligand therapy","volume":"50","author":"Kim","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026061914100547200_oyag173-B127","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin Ultrasound CT MR"},{"key":"2026061914100547200_oyag173-B128","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"5002 - [68Ga]Ga-PSMA-11 pet baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a vision substudy","volume":"40","author":"Kuo","year":"2022","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B129","doi-asserted-by":"publisher","first-page":"e17062","DOI":"10.1200\/JCO.2023.41.16_suppl.e17062","article-title":"Castration-resistant prostate cancer (CRPC) on PSMA-pet: imaging features, disease distribution, and a comparison to castration-sensitive prostate cancer (cspc)","volume":"41","author":"Hsu","year":"2023","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B130","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.21037\/tau-20-1047","article-title":"Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review","volume":"10","author":"de Kouchkovsky","year":"2021","journal-title":"Transl Androl Urol"},{"key":"2026061914100547200_oyag173-B131","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026061914100547200_oyag173-B132","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \"docetaxel era\": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"key":"2026061914100547200_oyag173-B133","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.esmoop.2023.101194","article-title":"Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy","volume":"8","author":"Oing","year":"2023","journal-title":"ESMO Open"},{"key":"2026061914100547200_oyag173-B134","doi-asserted-by":"publisher","first-page":"S965","DOI":"10.1016\/j.annonc.2023.09.2736","article-title":"1786p effect of rapid ultra-low prostate-specific antigen decline (UL PSA) in titan patients (PTS) with metastatic castration-sensitive prostate cancer (mCSPC) who received apalutamide (APA) plus androgen deprivation therapy (ADT)","volume":"34","author":"Merseburger","year":"2023","journal-title":"Ann Oncol"},{"key":"2026061914100547200_oyag173-B135","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2024.42.16_suppl.5079","article-title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304)","volume":"42","author":"Laughlin","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061914100547200_oyag173-B136","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.23.00323","article-title":"The past, present, and future of treatment intensification for metastatic hormone-sensitive prostate cancer","volume":"41","author":"McManus","year":"2023","journal-title":"JCO"},{"key":"2026061914100547200_oyag173-B137","author":"Unicancer Research","year":"2024"},{"key":"2026061914100547200_oyag173-B138","year":"2024"},{"key":"2026061914100547200_oyag173-B139","year":"2024"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag173\/68266151\/oyag173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag173\/68266151\/oyag173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag173\/68266151\/oyag173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:10:17Z","timestamp":1781892617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag173\/8675705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":139,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag173","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,11]]},"article-number":"oyag173"}}